#in vivo car t
Discover 2 curated intelligence briefings related to this specific topic.
Health & Medicine
The Delivery Gap: Why Genomic Discovery is Outstripping the Bio-Factory
The race to cure rare diseases has hit a systemic wall. While genomic sequencing identifies targets in days, the infrastructure to manufacture these bespoke cures takes years, creating a dangerous delivery gap that leaves thousands behind.
Read Analysis
Technology & Innovation
Scaling In Vivo Therapy Erases the Manufacturing Bottleneck
The shift toward in vivo CAR T and AAV gene therapies is fundamentally altering the economics of medicine. By eliminating the need to extract and modify cells outside the body, the industry is effectively pharmaceuticalizing gene therapy, though regulatory hurdles and clinical process inefficiencies still threaten the pace of adoption.
Read Analysis